

dolinnov

Dolinnov is revolutionizing the treatment of chronic pain by developing a non-opioid innovative therapy that address significant unmet medical needs.



Dolinnov is the world's first biotech company dedicated to targeting FXD2—a protein expressed in the dorsal root ganglion (DRG)—as a novel therapeutic approach for extreme chronic pain.

Our Innovation



New innovative target: FXD2 – Peripheral nervous system.



Delivery Innovation : Lipid Antisense Oligonucleotide (L-ASO) therapy designed to precisely silence mRNA sequences of FXD2.



Indications : Severe chronic pain.



Translational : Homologous sequence of our ASO designed for humans and animals ensuring seamless preclinical-to-clinical development.

Value proposition

- Chronic pain impacts **20% of the population in developed countries**.
- Our innovation fills a critical gap in pain management, **offering a breakthrough solution** for severe pain that remains inadequately treated in over 50% of patients.
- Optimized safety profile:** Eliminates CNS side effects and systemic toxicity, providing a safer alternative to opioids.
- Combining **cutting-edge ASO technology** with **advanced delivery system**.

Main publications

JCI insight PLoS scientific reports

Partners

Fondation Béatrice Denys

Montpellier Université

vcl

EUROBIOMED

inn

FONDATION Maladies Rares

Inserm Transfert

AXLR

FONDATION APICIL

APICIL

Key Milestones

- +1.6M€ raised in seed round**
 - company creation : Oct 2024
- Top ranked project**
 - 1#60 by a leading international big pharma company.
- 4 Patents**
 - under exclusive global license agreement with Inserm

Business Model

- Derisking preclinical POC for regulatory approval** before expanding to a broader range of indications.
- Exit strategy in 2028** after Phase I/II completion
- High-growth Market opportunity:**
 - Chronic Pain market : **\$70B**
 - ASO market growth : **\$6.1B** (2023) to **\$24B** (2033)

A Game-Changing Breakthrough for Chronic Pain Relief



FXYP2 – New innovative target

- > **Hyperexcitability regulator:** protein – gamma subunit of the Na⁺/K⁺-ATPase.
- > **PNS target:** No side effects on CNS.



L-ASO Precision therapeutic modality

- > **First in class L-ASO** for Chronic pain
- > **Conjugated proprietary chemistry**



A Broad spectrum of indications

- > Breakthrough data demonstrate exceptional efficacy in **neuropathic & inflammatory pain**.
- > **Lead Indication:** Cancer Pain

Patents

N°1
TECHNO

N°2
TARGET

N°3
PRODUCT

N°4
IV ROA

Our team



Dr. Stéphanie Venteo
CSO



Grégoire Serra
CEO



Dr. Jean Philippe Annereau
R&D Strategy



Pr. Céline Greco
KOL in Erythromelagia



Pr. Nadine Attal
KOL in pain Management



Dr. François Hubert
Regulatory Toxicology



Dr. Alain Toledano
KOL in Oncology



Dr. Leen Thielemans
CMO

Global development plan

